PD-L1 expressing circulating tumour cells in head and neck cancers

BACKGROUND: Blockade of the PD-1/PD-L1 immune checkpoint pathway is emerging as a promising immunotherapeutic approach for the management and treatment of head and neck cancer patients who do not respond to 1st/2nd line therapy. However, as checkpoint inhibitors are cost intensive, identifying patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulasinghe, Arutha, Perry, Chris, Kenny, Liz, Warkiani, Majid E., Nelson, Colleen, Punyadeera, Chamindie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434641/
https://www.ncbi.nlm.nih.gov/pubmed/28511705
http://dx.doi.org/10.1186/s12885-017-3316-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434641/
https://www.ncbi.nlm.nih.gov/pubmed/28511705
http://dx.doi.org/10.1186/s12885-017-3316-3

Ejemplares similares